|
|
Loss of heterozygosity analysis of chromosome
17p13.1-13.3 and its correlation with clinical outcome in medulloblastomas
Hye Lim Jung, Kyu-Chang Wang, Seung-Ki Kim,
Ki Woong Sung, Hong Hoe Koo, Hee Young Shin, Hyo Seop Ahn, Hyung Jin Shin and
Byung-Kyu Cho
Department of Pediatrics(H.L.J.,
K.W.S., H.H.K.) and Department of Neurosurgery (H.J.S.), Sungkyunkwan University
School of Medicine, Seoul; Department of Neurosurgery (K.-C.W., S.-K.K.,
B.-K.C.), Laboratory of Neuro-Oncology (K.-C.W., S.-K.K., B.-K.C.), Cancer
Research Institute, Department of Pediatrics (H.S.A.), Seoul National University
College of Medicine, Seoul, Korea
Cytogenetic and molecular genetic studies have shown that deletions on the
short arm of chromosome 17 distal to p53 locus are the most common genetic
events in medulloblastoma.
We examined the occurrences and frequencies of allelic deletions on chromosome
17p13.1-13.3 by loss of heterozygosity (LOH) analysis to investigate the
possible involvement of 17p13.1-13.3 in medulloblastoma development.
We also performed survival analysis to determine whether LOH analysis of
17p13.1-13.3 can be used to predict prognosis in medulloblastoma.
Loss of heterozygosity was analyzed by polymerase chain reaction on chromosome
17p13.1-13.3 using three microsatellite markers, TP53 on 17p13.1, D17S796 on
17p13.1-13.2, and D17S1574 on 17p13.3, in 17 medulloblastoma DNAs extracted
either from archival tissue or fresh frozen tissue specimens.
Allelic deletions were detected in five of 17 informative cases (29%) on TP53,
eight of 17 informative cases (47%) on D17S796, and four of 17 informative cases
(24%) on D17S1574.
Overall, nine of 17 cases (53%) showed LOH on chromosome 17p13.1-13.3.
The 5-year progression free survival (PFS) and 5-year overall survival rates
were identical (59%).
The 5-year PFS for nine medulloblastoma patients with LOH on 17p13.1-13.3 was
56%, and the 5-year PFS for eight medulloblastoma patients without LOH on
17p13.1-13.3 was 63%.
In our survival analysis, we did not find a significant association between
survival and LOH on 17p13.1-13.3.
Our results support the notion that deletions of chromosome 17p13.1-13.3 may be
involved in the pathogenesis of medulloblastoma.
From survival analysis, we conclude that LOH on chromosome 17p13.1-13.3 may not
be a significant predictor of prognosis in medulloblastoma.
PMID: 15072446 [PubMed - indexed for MEDLINE]
Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15072446
|
